Retatrutide Research Overview
A concise educational summary of published and publicly available research on retatrutide, an investigational triple hormone receptor agonist.
Research-Only Information
What is Retatrutide?
Retatrutide, also known as LY3437943, is described by Eli Lilly as an investigational once-weekly triple hormone receptor agonist. It is a single molecule designed to activate receptors for glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. These receptor pathways are being studied in relation to metabolic research, appetite regulation, glucose metabolism, energy expenditure, and body-weight regulation. This summary is provided for research-literature context only and does not describe availability, approval, recommendation, or intended use.
Mechanism Under Study
Published and company materials describe retatrutide as a triple hormone receptor agonist. Its research profile involves GIP, GLP-1, and glucagon receptor activity. This multi-receptor design is the basis for ongoing investigation into metabolic outcomes in clinical research settings.
Mechanism summaries are provided for research-literature context only and are not usage guidance.
Published Phase 2 Obesity Research
A Phase 2 study published in The New England Journal of Medicine evaluated retatrutide in adults with obesity or overweight. The study reported dose-dependent body-weight changes over 24 and 48 weeks. In the 12 mg group, the authors reported a mean body-weight change at 48 weeks of -24.2% compared with -2.1% for placebo. The authors concluded that the results supported further Phase 3 investigation. This summary reflects published study findings and is not a product claim.
Published Type 2 Diabetes Research
A Phase 2 trial published in The Lancet evaluated retatrutide across multiple doses in adults with type 2 diabetes. This research is summarized here only as published literature context. It should not be interpreted as treatment guidance, medical advice, or a recommendation for human or veterinary use.
Clinical Development Status
Retatrutide remains investigational. ClinicalTrials.gov lists ongoing studies evaluating its efficacy and safety in participants with obesity or overweight. Public trial records and sponsor materials should be treated as research and development information, not as product-use guidance.
Company-Reported Phase 3 Information
Eli Lilly announced Phase 3 TRIUMPH-1 results in May 2026. Lilly reported that participants taking 12 mg retatrutide lost an average of 70.3 lb, or 28.3% of body weight, over 80 weeks. This information is presented as company-reported information and should not be interpreted as independent or finalized peer-reviewed evidence unless a publication confirms that status.
Company-reported trial results are included for research-literature reference only. No dosing, administration, or usage guidance is provided.